Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 4, 2011, Pages 489-494

  Maki, Kevin C ^a   Lawless, Andrea L ^a   Kelley, Kathleen M ^a   Dicklin, Mary R ^a   Kaden, Valerie N ^a   Schild, Arianne L ^a   Rains, Tia M ^a   Marshall, John W ^a  

^a Provident Clinical Research   (United States)

Author keywords

dyslipidemia; hypercholesterolemia; Omega 3 fatty acids; statins; triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID ESTER; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BURPING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCRIPTION; PRIMARY ISOLATED HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 79955034378     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318210fca5     Document Type: Article

References (45)

1. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation. 1965;31:321-327.
2. Maki KC, Lubin BC, Reeves MS, et al. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J Clin Lipidol. 2009;3:33-38.
3. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-455.
4. Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-1098. Erratum 2007;370:220. (Pubitemid 46483662)
5. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlledtrial. Lancet. 2008;372:1223-1230.
6. Lovaza Prescribing Information. GlaxoSmithKline 2009. Available at: http://us.gsk.com/products/assets/us-lovaza.pdf Accessed November 28, 2010.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice, Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-1610. (Pubitemid 37012194)
8. Von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res. 2007;73:310-315. (Pubitemid 44937689)
9. Bays HE, Tighe AP, Sadovski R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6:391-409.
10. Brown WV, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with Type IIa or IIb hyperlipidemia. Arteriosclerosis. 1986;6:670-678. (Pubitemid 17190167)
11. Sullivan DR, Sanders TA, Trayner IM, et al. Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients andnormal subjects ingesting fish oil. Atherosclerosis. 1986;61:129-134. (Pubitemid 16071177)
12. Harris WS, Ginsberg H, Arunakul N, et al. Safety and efficacy ofP-OM3 in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385-391. (Pubitemid 28078682)
13. Harris WS, Lu G, Rambjør GS, et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am JClin Nutr. 1997;66:254-260. (Pubitemid 27360322)
14. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285-297. (Pubitemid 29166909)
15. Calabresi L, Donati D, Pazzucconi F, et al. POM3 in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000;148:387-396. (Pubitemid 30064470)
16. Maki KC. Fibrates for the treatment of the metabolic syndrome. Curr Atheroscler Rep. 2004;6:45-51.
17. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697-705. (Pubitemid 38478692)
18. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol. 2005;95:462-468. (Pubitemid 40247539)
19. Davidson MH, Bays HE, Stein E, et al; for the TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006;29:268-273. (Pubitemid 43865706)
20. Davidson MH, Stein EA, Bays HE, et al; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemia patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354-1367. (Pubitemid 47348116)
21. Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12-24.
22. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemia: mechanisms of action and rational prescribing. Vasc Health RiskManag. 2008;4:991-1000.
23. Maki KC, McKenney JM, Reeves MS, et al. Effects of addingprescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. 2008;102:429-433. Erratum 2008;102:1425.
24. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther. 2008;6:1319-1330.
25. Moutzouri E, Kei A, Elisaf MS, et al. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health RiskManag. 2010;6:525-539.
26. TriCor Prescribing Information. Abbott Laboratories 2008. Available at: http://www.rxabbott.com/pdf/tricorpi.pdf. Accessed November 28, 2010.
27. Trilipix Prescribing Information. Abbott Laboratories 2008. Available at: http://www.rxabbott.com/pdf/trilipix-pi.pdf. Accessed November 28, 2010.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-3421.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
30. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorable changes by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113: 1556-1563. (Pubitemid 43739414)
31. Maki KC, Dicklin MR, Davidson MH, et al; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Baseline lipopro-tein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy. Am J Cardiol. 2010;105:1409-1412.
32. Bays HE, McKenney J, Maki KC, et al. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc. 2010;85:122-128.
33. Chan DC, Watts GF, Barrett PHR, et al. Regulatory effects of HMG CoA reductase inhibitors and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002; 51:2377-2386. (Pubitemid 34827385)
34. Chan DC, Watts GF, Mori TA, et al. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77:300-307. (Pubitemid 36133369)
35. Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3: 332-340.
36. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287-1295. (Pubitemid 17181567)
37. Bays HE, Maki KC, McKenney J, et al. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin. 2010;26:907-915.
38. Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002;90:i30-i47.
39. Choi CU, Seo HS, Lee EM, et al. Statins do not decrease small, dense low-density lipoprotein. Tex Heart Inst J. 2010;37:421-428.
40. Nordøy A, Bonaa KH, Nilsen H, et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med. 1998;243:163-170. (Pubitemid 28156665)
41. Watts GE, Dimmitt SB. Fibrates, dyslipoproteinemia and cardiovascular disease. Curr Opin Lipidol. 1999;10:561-574.
42. Appel LJ, Miller ER 3rd, Seidler AJ, et al. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993;153:1429-1438. (Pubitemid 23191050)
43. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993;88:523-533. (Pubitemid 23228051)
44. Geleijnse JM, Giltay EJ, Grobbee DE, et al. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. J Hypertens. 2002;20:1493-1499. (Pubitemid 34921171)
45. Hartweg J, Farmer AJ, Holman RR, et al. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 2007;50:250-258.